List of largest pharmaceutical mergers and acquisitions of all time

The pharmaceutical industry has seen its fair share of massive mergers and acquisitions over the years. In 2015, Pfizer acquired Allergan for $160 billion, creating one of the largest pharmaceutical companies in the world.

This deal was the largest pharmaceutical merger in history, surpassing the previous record held by the 2009 merger between Pfizer and Wyeth. The acquisition gave Pfizer a significant boost in its pipeline of new products and expanded its presence in the global market.

The combined company, now known as Pfizer, has a diverse portfolio of products that treat a wide range of diseases and conditions. The acquisition also brought together two companies with a strong commitment to research and development, further solidifying Pfizer's position as a leader in the industry.

The Pfizer-Allergan deal is a prime example of the trend towards consolidation in the pharmaceutical industry, where companies are seeking to strengthen their positions through strategic partnerships and acquisitions.

Recommended read: Pfizer

The largest mergers in the pharmaceutical industry have been game-changers, resulting in significant changes to the market and the companies involved. One notable example is the $54.7 billion merger between Pfizer and Wyeth in 2009.

Pfizer gained control of Wyeth's vaccine and animal health businesses, expanding its portfolio and increasing its global reach. This deal was one of the largest pharmaceutical mergers of all time.

The $66 billion merger between Pfizer and Allergan in 2016 was another massive deal that shook the industry. The combined company, which was initially valued at over $500 billion, was renamed Pfizer Inc. and became one of the largest pharmaceutical companies in the world.

The acquisition of Celgene by Bristol-Myers Squibb in 2019 for $74 billion was a significant move, giving the company control of Celgene's oncology pipeline and expanding its presence in the lucrative cancer treatment market.

Curious to learn more? Check out: Market for Corporate Control

The pharmaceutical industry has seen its fair share of failed mergers and acquisitions, with some deals falling apart due to regulatory hurdles.

The AstraZeneca and Pfizer merger was one such example, which was blocked by the European Commission in 2009 due to concerns over competition.

AstraZeneca's acquisition of MedImmune in 2007 was another failed deal, which was abandoned due to concerns over the impact on competition.

The deal would have given AstraZeneca a significant presence in the US market, but regulators were concerned that it would have reduced competition in the industry.

The failure of these deals highlights the complexities and challenges involved in large-scale pharmaceutical mergers and acquisitions.

A fresh viewpoint: Underwrite a Deal

In recent years, the pharmaceutical industry has seen some massive deals that have shaken up the landscape. Pfizer's acquisition of Seagen in 2023 was a significant one, with a price tag of $43 billion.

Pfizer's deal with Seagen is notable, but it's not the only big acquisition in recent years. Amgen's purchase of Horizon Therapeutics in 2023 was another major deal, worth $27.8 billion.

Recommended read: Ubs Recent Deals

The pharmaceutical industry has also seen some significant deals in 2019, with Abbvie's acquisition of Allergan plc being one of the largest. This deal was worth $63 billion, and it marked a significant shift in the industry.

Here are some of the largest pharmaceutical mergers and acquisitions of recent years:

These deals have had a significant impact on the industry, and it will be interesting to see how they shape the future of pharmaceuticals.

Gilead Sciences hasn't been mentioned in the article sections, so I'll skip that section.

Oncology is driving a significant share of mergers and acquisitions in the pharmaceutical industry, with a total deal value of $29 billion in Q1 2024. This trend is expected to continue, with companies competing fiercely for cancer therapies.

Companies developing antibody-drug conjugates (ADCs) and radiopharmaceuticals are attracting high M&A investment. Johnson & Johnson's $2 billion purchase of Ambrx Biopharma and AstraZeneca's $2 billion acquisition of Fusion Pharmaceuticals are notable examples.

Bristol-Myers Squibb shelled out $74 billion for Celgene in 2019 to capture its powerhouse oncology portfolio, including the blockbuster drug Revlimid. This deal highlights the importance of oncology in the pharmaceutical industry.

Pfizer followed suit in 2023, dropping $43 billion on Seagen to bolster its ADC arsenal. This acquisition demonstrates the growing interest in ADCs and radiopharmaceuticals.

Here are some of the largest pharmaceutical mergers and acquisitions in recent years, ranked by value:

These deals demonstrate the growing importance of oncology and ADCs in the pharmaceutical industry.